Visual Prognosis in Giant Cell Arteritis
References (28)
- et al.
The ocular lesions of temporal arteritis
Am J Ophthalmol
(1958) Temporal arteritis as a cause of blindness. Review of the literature and report of a case
Am J Ophthalmol
(1950)- et al.
Clinical manifestations of giant cell (temporal) arteritis
Clin Rheumatic Dis
(1980) Reversal of blindness in temporal arteritis with methylprednisolone [letter]
Lancet
(1978)- et al.
Treatment of temporal arteritis with ocular involvement
Am J Med
(1986) - et al.
Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis
Ophthalmology
(1992) - et al.
Manifestations of giant cell arteritis
Med Clin North Am
(1977) - et al.
Arteritis of the temporal vessels
Lancet
(1938) - et al.
Neurologic aspects of temporal arteritis
Neurology
(1960) - et al.
Giant cell arteritis
Acta Med Scand Suppl
(1982)
Temporal arteritis: clinical aids to diagnosis
J Rheumatol
(1988)
Temporal arteritis-progressive affection of vision during high-level corticosteroid therapy. A case report
Acta Med Scand
(1979)
Giant cell arteritis: loss of vision during corticosteroid therapy
J Intern Med
(1989)
Temporal arteritis. Occurrence of ocular complications 7 years after diagnosis
Br J Ophthalmol
(1972)
Cited by (332)
Accuracy of self-reported diagnoses of polymyalgia rheumatica and giant cell arteritis in the French prospective E3N- EPIC cohort: A validation study
2024, Seminars in Arthritis and RheumatismConsensus statement on the processing, interpretation and reporting of temporal artery biopsy for arteritis
2023, Cardiovascular PathologyGiant cell arteritis: Update on clinical manifestations, diagnosis, and management
2023, European Journal of Internal MedicineDiagnosis of giant cell arteritis using clinical, laboratory, and histopathological findings in patients undergoing temporal artery biopsy
2022, Clinical Neurology and NeurosurgeryHigh risk and low prevalence diseases: Giant cell arteritis
2022, American Journal of Emergency MedicineCitation Excerpt :Treatment with steroids should be initiated as soon as GCA is suspected [33,60-62]. Management should not be delayed while awaiting TAB, as delayed treatment could result in acute ischemic optic neuropathy and permanent vision loss [63]. For patients with high suspicion of GCA and symptoms of vision lossor involvement of large vessels (such as aortitis), administration of methylprednisolone 1000 mg IV once per day, for 3 days, is recommended [33,39,61].
Supported in part by NIH grant EY08039 (William M. Bourne), an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York, and by Mayo Foundation, Rochester, Minnesota.
Copyright © 1993 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved.